Enveric Biosciences, Inc. (ENVB)
NASDAQ: ENVB · IEX Real-Time Price · USD
0.900
-0.034 (-3.64%)
At close: Apr 25, 2024, 3:58 PM
0.898
-0.003 (-0.28%)
After-hours: Apr 25, 2024, 6:25 PM EDT

Enveric Biosciences Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018201720162015
Market Capitalization
7342986749--
Market Cap Growth
--30.19%-85.19%265.82%40.49%-17.79%-85.95%---
Enterprise Value
41-131266115144
PE Ratio
-0.17-0.17-0.23-0.60-1.16-2.36-0.35-4.40--
PS Ratio
------0.161.01--
PB Ratio
3.361.540.301.312.34-3.130.642.53--
P/FCF Ratio
-0.21-0.21-0.24-2.51-2.05-8.77-2.70-17.90--
P/OCF Ratio
-0.21-0.21-0.25-2.55-2.05-8.77-2.69-17.93--
EV/Sales Ratio
------0.251.060.100.21
EV/EBITDA Ratio
-0.04-0.040.68-0.22-1.02-2.74-1.55-6.70-0.83-7.95
EV/EBIT Ratio
-0.04-0.040.67-0.21-1.00-2.74-1.09-4.72-0.63-6.07
EV/FCF Ratio
-0.05-0.050.75-1.03-1.65-9.84-4.20-18.74-1.34-4.00
Debt / Equity Ratio
--0.000.01--0.410.480.370.4324.12
Debt / EBITDA Ratio
--0.000.00--0.32-0.75-0.94-1.14-11.60
Debt / FCF Ratio
--0.00-0.02--1.14-2.03-2.62-1.84-5.83
Quick Ratio
0.980.984.446.342.320.020.630.450.740.80
Current Ratio
1.531.534.616.483.350.060.690.480.790.84
Asset Turnover
0000001.020.991.371.62
Interest Coverage
---3801.13-5469.31-14.42-28.46-13.45-18.94-7.69-2.95
Return on Equity (ROE)
-355.00%-355.00%-89.60%-169.60%-69.20%-28.80%-99.50%-74.40%-61.70%-98.40%
Return on Assets (ROA)
-191.00%-191.00%-67.70%-134.20%-31.70%-11.10%-46.10%-22.70%-10.60%-6.50%
Return on Capital (ROIC)
-840.78%-840.78%-186.04%-287.44%-164.46%214.38%-44.76%-40.92%-32.23%-12.23%
Earnings Yield
-265.95%-578.54%-434.91%-167.81%-86.04%-42.45%-282.02%-22.71%--
FCF Yield
-214.53%-466.67%-410.17%-39.91%-48.74%-11.41%-37.05%-5.59%--
Buyback Yield / Dilution
-49.31%-49.31%-206.13%-310.48%-8.82%-2122.43%-58.76%-14.65%-17.75%-16976.92%
Total Shareholder Return
-49.31%-49.31%-206.13%-310.48%-8.82%-2122.43%-58.76%-14.65%-17.75%-16976.92%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).